Efficacy and safety of sulforaphane for treatment of mild to moderate depression in patients with history of cardiac interventions: A randomized, double-blind, placebo-controlled clinical trial
Ghazizadeh-Hashemi F, Bagheri S, Ashraf-Ganjouei A, Moradi K, Shahmansouri N, Mehrpooya M, Noorbala AA, Akhondzadeh S
Psychiatry and clinical neurosciences · 35 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
- Consumo medido con
- No se indica
Quién lo pagó
- Financiación
- Financiación independiente
- Universidad u hospital
- Tehran University of Medical Sciences and Health Services
- Subvenciones
- Tehran University of Medical Sciences and Health Services (46003)
Según 1 financiador declarado.
Publicación
- Publicado
- 2021-05-25 · Psychiatry Clin Neurosci · vol. 75 · número 8 · págs. 250–255
- Editorial
- Wiley
- Citado
- 37 citas · más que el 90% de estudios similares · 2.6× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 47 trabajos
- Acceso
- De pago
- Áreas de investigación
- Treatment of Major Depression · Cardiac Health and Mental Health · Tryptophan and brain disorders
- Palabras clave
- sulforaphane, depression, cardiac interventions, percutaneous coronary intervention, coronary artery bypass grafting, antidepressant efficacy, drug safety, adverse effects, remission
- MeSH
- humans, isothiocyanates, sulfoxides, treatment outcome, double-blind method, depression, adult, aged, middle aged, female, male, percutaneous coronary intervention
8 autores
- Fatemeh Ghazizadeh‐Hashemi🇮🇷Tehran University of Medical Sciences
- Sayna Bagheri🇮🇷Roozbeh Hospital; Tehran University of Medical Sciences
- Amir Ashraf‐Ganjouei🇮🇷Roozbeh Hospital; Tehran University of Medical Sciences
- Kamyar Moradi🇮🇷Roozbeh Hospital; Tehran University of Medical Sciences
- Nazila Shahmansouri🇮🇷Tehran University of Medical Sciences
- Maryam Mehrpooya🇮🇷Tehran University of Medical Sciences
- Ahmad-Ali Noorbala🇮🇷Tehran University of Medical Sciences
- Shahin Akhondzadeh🇮🇷 · autor de correspondenciaRoozbeh Hospital; Tehran University of Medical Sciences
Resumen
El texto original del estudio, en el idioma en que se publicó.
Aim
Depression has been recognized as one of the disorders associated with cardiac interventions such as percutaneous coronary intervention (PCI) or coronary artery bypass graft surgery (CABG). In the present study, we evaluated the efficacy and safety of sulforaphane in treatment of depression induced by cardiac interventions.
Methods
After initial screening, 66 patients with previous history of at least one cardiac intervention and current mild to moderate depression were randomly assigned to two parallel groups receiving either sulforaphane (n = 33) or placebo (n = 33) for six successive weeks. Efficacy was assessed using the Hamilton Rating Scale for Depression (HAM-D) at baseline and week 2, 4, and 6. Safety of the treatments was checked during the trial period.
Results
Sixty participants completed the clinical trial (n = 30 in each group). Baseline demographic and clinical parameters were all similar among groups. Repeated measures analysis indicated that the sulforaphane group exhibited greater improvement in HAM-D scores throughout the trial (P < 0.001). Response to treatment (≥50% reduction in the HAM-D score) rate was higher in the sulforaphane group at trial endpoint (30% vs 6.67%, P = 0.042). Remission (HAM-D score ≤ 7) rate was also higher in the sulforaphane group; however, the difference was not significant (23.33% vs 3.33%, P = 0.052). Finally, no significant difference was observed between the two groups in terms of frequency of side effects.
Conclusions
Sulforaphane could safely improve depressive symptoms induced by cardiac interventions. Further clinical trials with larger sample sizes and longer follow-up periods are warranted to confirm our results.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.